NPPA allows differential price for Meril's biodegradable cardiac stent
The National Pharmaceutical Pricing Authority (NPPA) invoked the para 32 (ii) of the Drug Price Control Order, 2013 to grant the exemption to the indigenously developed stent
)
Explore Business Standard
Associate Sponsors
Co-sponsor
The National Pharmaceutical Pricing Authority (NPPA) invoked the para 32 (ii) of the Drug Price Control Order, 2013 to grant the exemption to the indigenously developed stent
)
Already subscribed? Log in
Subscribe to read the full story →
3 Months
₹300/Month
1 Year
₹225/Month
2 Years
₹162/Month
Renews automatically, cancel anytime
Over 30 premium stories daily, handpicked by our editors


News, Games, Cooking, Audio, Wirecutter & The Athletic
Digital replica of our daily newspaper — with options to read, save, and share


Insights on markets, finance, politics, tech, and more delivered to your inbox
In-depth market analysis & insights with access to The Smart Investor


Repository of articles and publications dating back to 1997
Uninterrupted reading experience with no advertisements


Access Business Standard across devices — mobile, tablet, or PC, via web or app
First Published: Feb 28 2020 | 11:16 PM IST